Vincent Bischoff

Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France.

CNRS Innovation SA is a French company that focuses on research and innovation. The company is based in Boulogne-Billancourt, France. The company has been in the industry for over 30 years and have a team of experts who provide services to clients. The company has signed numerous operating contracts since 2012 and has supported many start-ups since 2019. The company has subsidiaries and are ultimately controlled by the Centre National de la Recherche Scientifique.

BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands.

ARTHEx Biotech S.L. engages in the development of antisense RNA (ribonucleic acid) treatments against genetic diseases. It offers Anti-microRNAs for the treatment of unmet genetic diseases. The company was founded by Beatriz Llamus? and Rub?n Artero on September 27, 2019 and is headquartered in Paterna, the United Kingdom.